About this book:

Abbott Laboratories traces its origins to 1888 when Dr. Wallace C. Abbott founded the Abbott Alkaloidal Company to produce standardized “dosimetric granules” that offered precise, reliable dosing—a radical departure from the inconsistent preparations of the era. Early growth was driven by a commitment to scientific rigor, the launch of the influential *Alkaloidal Clinic* journal, and expansion beyond alkaloids into synthetic vitamins, anesthetics, and hospital‑based parenteral solutions. World War I prompted Abbott to develop domestic chemical manufacturing, producing procaine and other essential medicines, and the company officially became Abbott Laboratories in 1915. During the Great Depression it maintained research and vitamin production, and in World War II it played a pivotal role in the mass‑production of penicillin and supplied a wide range of medicines, blood plasma, and nutritional products to the Allied forces.

The post‑war era ushered in a boom of antibiotics—most notably erythromycin in 1952—and continued advances in vitamins and hospital products. The 1960s marked Abbott’s strategic entry into diagnostics with the acquisition of the Radio‑Pharmaceutical Company, leading to breakthrough hepatitis B surface‑antigen tests that safeguarded the global blood supply. The 1970s and 1980s saw intensified R&D, automation of immunoassays (the ABA‑100 and later ARCHITECT systems), and a rapid response to the AIDS epidemic that yielded the first FDA‑licensed HIV antibody screening test in 1985. Simultaneously, Abbott embraced biotechnology and brought to market the cardiovascular drug Isoptin (verapamil) while building expertise in recombinant DNA technology that would later underpin its biologics pipeline.

The turn of the millennium was defined by bold acquisitions: Alza Corporation (advanced drug delivery) in 1999, Knoll Pharmaceutical Company (including the monoclonal antibody Humira) in 2001, and Guidant Corporation’s vascular intervention business (coronary stents) in 2006, followed by St. Jude Medical in 2017. These moves transformed Abbott into a leader in immunology, interventional cardiology, and diagnostics. In response to evolving market dynamics, Abbott spun off its research‑based pharmaceutical business as AbbVie in 2013, retaining a focused portfolio of medical devices (stents, structural‑heart devices, neuromodulation), diagnostics (central‑lab and point‑of‑care systems such as ARCHITECT, i‑STAT, and molecular platforms), nutritionals (infant formulas like Similac, adult health brands Ensure and Glucerna, and specialized medical nutrition), and a legacy established‑pharma segment serving emerging markets. Innovation continued with the XIENCE V drug‑eluting stent, the FreeStyle Libre continuous glucose monitoring system that revolutionized diabetes care, and expanding diagnostic capabilities during the COVID‑19 pandemic. Throughout its history Abbott has emphasized global reach, localized manufacturing, emerging‑market expansion, corporate social responsibility, environmental sustainability, and a culture of scientific rigor, quality, and innovation that has shaped healthcare, economies, and societies worldwide for nearly 140 years.

What You'll Find Inside:

• The founding vision of Dr. Wallace C. Abbott and his pioneering work in standardizing medicines through dosimetric granules to ensure precise, reliable drug dosing
• Abbott's critical contributions during global crises including penicillin mass production in WWII and developing the first FDA-licensed HIV antibody test during the AIDS epidemic
• Strategic diversification into four core business segments: medical devices (stents, cardiovascular technologies), diagnostics (laboratory and point-of-care systems), nutritionals (infant formula to adult health), and established pharmaceuticals
• Global expansion through establishing manufacturing facilities, sales networks, and local partnerships across emerging and developed markets to serve diverse patient populations worldwide
• Continuous innovation driven by robust R&D leading to breakthrough products like Humira (biologic), XIENCE V stent (cardiovascular device), and FreeStyle Libre (diabetes monitoring system)

Who's It For:

This book is ideal for healthcare professionals, business students, pharmaceutical industry professionals, and anyone interested in the history of medical innovation. It provides valuable insights into how Abbott Laboratories navigated historical challenges, drove scientific breakthroughs, and built a sustainable global healthcare enterprise through strategic vision and adaptability.